A FIRST-IN-HUMAN, PHASE 1, DOSE-ESCALATION STUDY OF DINACICLIB, A NOVEL CYCLIN-DEPENDENT KINASE INHIBITOR, ADMINISTERED WEEKLY IN SUBJECTS WITH ADVANCED MALIGNANCIE

Friday, July 26, 2013

Read the Story Here

Related Posts

Discover more posts like this.

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12CMutated Metastatic Colorectal Cancer

Apr 10, 2024

Dr. Minal Barve

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Mar 28, 2024

Dr. Minal Barve

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

Mar 6, 2024

Douglass Orr, MD
See All Posts